Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06358807
Other study ID # M2023438
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date January 1, 2024
Est. completion date December 31, 2026

Study information

Verified date March 2024
Source Peking University Third Hospital
Contact Qinwei Guo, MD
Phone +86 18601129252
Email guoqinwei@vip.sina.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this clinical trial is to learn if combined local injection of platelet rich plasma (PRP) gel adds clinical efficacy to isolated arthroscopic microfracture in treatment of osteochondral lesion of the talus (OLT). The interface integration of the injured area will also be assessed via radiographic follow-up. The main questions it aims to answer are: - Does arthroscopic microfracture combined with PRP gel injection improve ankle function of participants based on American Orthopedic Foot and Ankle Society (AOFAS) Score? - Does arthroscopic microfracture combined with PRP gel injection improve interface integration of the injured cartilage on magnetic resonance imaging (MRI)? Researchers will compare arthroscopic microfracture with concomitant local injection of PRP gel to isolated microfracture to see if intraoperative PRP gel injection adds clinical efficacy to isolated arthroscopic microfracture in treatment of OLT. Participants will: - Undergo either isolated arthroscopic microfracture or microfracture with intraoperative injection of PRP gel - Receive clinical follow-up 3, 6, 12, and 24 months after surgery and answer scales of ankle function assessment - Take MRI preoperatively and 6, 12 and 24 months after surgery


Recruitment information / eligibility

Status Recruiting
Enrollment 70
Est. completion date December 31, 2026
Est. primary completion date January 1, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: - Chronic ankle pain, diagnosed as osteochondral lesion of the talus; - Lesion size = 1.5 cm2 or the diameter of the lesion = 1.5 cm; - Conservative treatment of at least 3 months fails to relieve symptoms; - Willingness to voluntarily participate in the trial and to sign informed consent. Exclusion Criteria: - Varus or valgus deformity of the ankle of more than 5 degrees; - Grade III injury of the lateral collateral ligament of ankle; - Chronic synovitis (rheumatoid arthritis, pigmented villous nodular synovitis, etc.); - Joint fibrosis, stiffness, and significantly restricted range of motion; - Evidence of moderate to severe knee osteoarthritis on plain radiographs; - Failure to complete the rehabilitation protocol as required; - Patient medically not fit for surgery, radiographs or MRI; - For women, pregnant, planning to be pregnant or lactating.

Study Design


Intervention

Procedure:
Arthroscopic microfracture with intraoperative local PRP gel injection
Arthroscopic microfracture: An anteromedial portal and an anterolateral portal are routinely established. A diagnostic arthroscopy is performed. Defects of superficial cartilage, cystic components, and necrotic bone are debrided arthroscopically with curette and shaver to a stable circumferential rim. Microfracture awls are introduced and subchondral channels to 4-6 mm in depth are created, spacing the channels 3 to 5 mm apart across the entire surface of the lesion. PRP preparation and local injection: PRP is harvested using a PRP preparation kit via centrifugation. Fifty milliliters of autologous venous blood are drawn from the patient and processed. Platelet count is measured for quality control. On average 4 ml of (range 3-6) PRP is obtained and mixed with thrombin calcium agent in preparation for PRP gel. PRP gel is administered to the injured area using a blunt and long-tip injector, with direct visualization under arthroscope.
Isolated microfracture
Arthroscopic microfracture: An anteromedial portal and an anterolateral portal are routinely established. A diagnostic arthroscopy is performed. Defects of superficial cartilage, cystic components, and necrotic bone are debrided arthroscopically with curette and shaver to a stable circumferential rim. Microfracture awls are introduced and subchondral channels to 4-6 mm in depth are created, spacing the channels 3 to 5 mm apart across the entire surface of the lesion.

Locations

Country Name City State
China Peking University Third Hospital Beijing

Sponsors (1)

Lead Sponsor Collaborator
Peking University Third Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary American Orthopedic Foot and Ankle Society Score (AOFAS) The scale of AOFAS score will be answered by participants during clinic follow-up preoperatively, and 3, 6, 12 and 24 months after surgery. The primary outcome measure will be the AOFAS collected 24 months post-surgery. Pre-surgery and 3, 6, 12 and 24 months after surgery
Secondary Foot and Ankle Outcome Score (FAOS) The scale of FAOS score will be answered by participants during clinic follow-up preoperatively, and 3, 6, 12 and 24 months after surgery. Pre-surgery and 3, 6, 12 and 24 months after surgery
Secondary Ankle Activity Score (AAS) The scale of AAS score will be answered by participants during clinic follow-up preoperatively, and 3, 6, 12 and 24 months after surgery. Pre-surgery and 3, 6, 12 and 24 months after surgery
Secondary Visual Analogue Scale (VAS) The scale of VAS score will be answered by participants during clinic follow-up preoperatively, and 3, 6, 12 and 24 months after surgery. Pre-surgery and 3, 6, 12 and 24 months after surgery
Secondary Patient Satisfaction Patient satisfaction will be graded as 0-10 and collected 24 months after surgery. Final follow-up (24 months after surgery)
Secondary Magnetic Resonance Observation of Cartilage Repair Tissue (MOCART) MOCART score will be assessed on magnetic resonance imaging 12 and 24 months after surgery. Twelve and 24 months after surgery
Secondary Return-to-Sport Rate The rate and time point of participants returning to sports will be continuously followed during clinic follow-up and will be overall collected 24 months after surgery. Final follow-up (24 months after surgery)
Secondary Complications Complications, including infection,hematoma, stiffness, recurrent ankle pain will be continuously followed during clinic follow-up and will be overall collected 24 months after surgery. Final follow-up (24 months after surgery)
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04475341 - Osteochondral Lesions Under 15mm2 of the Talus; is Iliac Crest Bone Marrow Aspirate Concentrate the Key to Success? N/A
Enrolling by invitation NCT03856021 - Microfracture vs. Microfracture and BMAC for Osteochondral Lesions of the Talus N/A
Not yet recruiting NCT05476692 - Clinical Outcome of Surgical Treatment for Osteochondral Lesions of the Talus
Active, not recruiting NCT02345564 - Clinical and Radiological Results of Osteochondral Repair Using MaioRegen in Knee and Ankle Surgery N/A
Active, not recruiting NCT01347892 - DeNovo NT Ankle LDC Study N/A
Active, not recruiting NCT03750253 - Extracorporeal Shock Wave Therapy for Pain-Relief After Arthroscopy for Osteochondral Lesions of the Talus N/A
Completed NCT04194970 - Monitoring of Weight Bearing Protocols Via Mobile Application and Pressure Sensors. N/A
Enrolling by invitation NCT02338375 - Safety and Efficacy of Allogenic Umbilical Cord Blood-derived Mesenchymal Stem Cell Product Phase 0
Withdrawn NCT05741983 - AMIC vs. MFx in the Ankle N/A
Enrolling by invitation NCT04132076 - Treatment Outcome After Ankle Joint Surgeries